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Abstract 
Purpose: To demonstrate the effect of glabridin on peritoneal function and residual renal function (RRF) 
in peritoneal dialysis (PD) patients. 
Methods: Twenty five patients (age range, 24 - 58 years) with a glomerular filtration rate of above 2 
mL/min/1.73 m2 and on PD were subjected to glabridin therapy. The patients were treated daily with 
glabridin (30 mg) for 6 months. The baseline parameters for serum high-sensitivity C-reactive protein 
(hs-CRP), vascular endothelial growth factor (VEGF), and transforming growth factor β (TGF-β) were 
compared with those found after 6 months of glabridin treatment. In addition, end-to-initial dialysate 
concentration of glucose (D4/D0 glucose), dialyzer clearance of urea (K), dialysis time (t), volume of 
distribution of urea (V), peritoneal transport status as well as dialysate cancer antigen 125 (CA125) 
were also compared.  
Results: The results revealed a significant increase in mean dialysate CA125 after glabridin treatment 
(25.6 ± 2.7 U/mL) compared with baseline value (19.7 ± 3.2 U/mL). However, serum hs-CRP, VEGF, 
TGF-β, CTGF, daily ultrafiltration, D4/D0 glucose, Kt/V, and peritoneal transport status remained 
unaffected. Residual glomerular filtration rate in all the patients decreased. Glabridin treatment also led 
to a decrease in the decline of peritoneal function, suppression of elevation of profibrotic markers, and 
increased mesothelial cell mass in PD patients. 
Conclusion: Thus, glabridin is a potent candidate for the treatment of residual kidney function in 
dialysis patients. 
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There is development of alterations in the 
peritoneal membrane due to long term PD on 
regular contact with bio-incompatible 
components of dialysis solution [1]. PD is 
characterised by peritoneal damage resulting in 
ultrafiltration (UF) capacity decline, 
submesothelial fibrosis, extracellular matrix 
accumulation, and neoangiogenesis [2]. To 
repair tissues there is a renin–angiotensin–
aldosterone system (RAAS) which acts in 
association with cytokine transforming growth 
factor β (TGF-β) [3]. For the prevention of 
peritoneal membrane damage angiotensin 
converting-enzyme inhibitors (ACEIs) and 
angiotensin II receptor blockers (ARBs) are 
reported to play a vital role [4]. 
 
It   is   reported   that   mineralocorticoid  receptor  
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antagonists improve the prognosis of patients 
with kidney injury [5]. Some of the drug 
candidates like irbesartan, spironolactone, and 
irbesartan plus spironolactone were found to 
lower peritoneal fibrosis in rats with bacterial 
peritonitis [6]. Residual renal function (RRF), the 
measure of dialysis adequacy and creatinine 
clearance [7] from the kidney accounts for most 
of the variability in the requirement for dialysis 
[8]. It is the major determinant of morbidity and 
mortality in patients on PD [9]. Although ACEIs 
and ARBs have been shown to slow the decline 
in RRF [10]. 
 
Glycyrrhiza plant, a member of the Leguminosae 
family has been medicinally used for more than 
4,000 years [11]. Glabridin (Fig. 1), isolated from 
licorice (root and stolon of Glycyrrhiza) has been 
reported to possess various pharmacological 
activities like cytotoxic, antimicrobial, anti-fatigue, 
estrogenic and anti-proliferative activity against 
human breast cancer cells [12]. It also affects 
melanogenesis, inflammation, low density 
lipoprotein oxidation and protection of 
mitochondrial functions from oxidative stress 
[13]. In the present study, we devised an 
experiment to investigate the protective effects of 











Thirty patients (age range, 24 - 58 years) with 
glomerular filtration rate (GFR) >2  mL/min/1.73 
m2 and who had no history of taking an ACEI or 
ARB for at least 6 months and had been on PD 
for at least 5 months were enrolled for glabridin 
treatment study. All the enrolled patients were 
free from underlying medical condition that 
involves treatment with ACEI or ARB, 
hyperpotassemia, or an active infection or a 
peritonitis episode within the preceding 3 month. 
All the related information such as age, sex, body 
mass index, blood pressure, cause of end-stage 
renal failure, and time spent on PD was recorded 
for all the patients. The patients were daily given 
30 mg of glabridin for 6 months and were 
analysed every month in PD clinic. The patients 
were recommended regular diet containing 1.0 -
1.3 g/kg protein daily and limited sodium 




The present study was approved by the ethical 
committee of Zhongshan Hospital, Fudan 
University (no. 2012 93; Shanghai, China) and 
conducted in accordance with the declaration of 
Helsinki [14]. A written consent was taken from 
all the patients to ensure that they are aware of 




For biochemical investigation, the blood samples 
of fasting patients were collected for blood cell 
count, and serum levels of glucose, blood urea 
nitrogen, creatinine, sodium, potassium, calcium, 
phosphorus, total protein, albumin and 
triglycerides. Total cholesterol, low-density and 
very-low-density lipoprotein cholesterol were 
measured by standard enzymatic methods. 
 
Nephelometric method (Dade Behring, Deerfield, 
IL, USA) was used for high sensitivity C-reactive 
protein (hs-CRP) measurement. For the 
measurement of serum vascular endothelial 
growth factor (VEGF), TGF-β, and connective 
tissue growth factor (CTGF) blood samples were 
centrifuged at 12000 cycles per second for 2 min.  
 
For enzyme-linked immunosorbent assay using a 
commercial kit (Invitrogen, Camarillo, CA, USA) 
supernatant was stored at -80 °C. The clearance 
of urea and creatinine from renal and peritoneal 
urine and dialysate 24 h collections was 
measured. Serum urea and creatinine were 
determined simultaneously and residual GFR 
was defined as the average of the 24 h urinary 
urea and creatinine clearances. The standard 
peritoneal equilibration test using dialysate 
containing 3 % glucose was used for peritoneal 
function like daily UF and glucose transport. The 
electrochemiluminescence assay (Elecys CA125 
II kit with an Elecsys 2010 immunoassay 
analyzer: Roche Diagnostics, Mannheim, 
Germany) was used to measure cancer antigen 
125 (CA125) concentrations in the 24h peritoneal 
effluent collection.  
 
Statistical analysis  
 
The Statistical Package for Social Sciences 
(version 15.0 for Windows: SPSS, Chicago, IL, 
USA) was used for statistical analysis. One-way 
analysis of variance (ANOVA) was used to 
determine whether there are any statistically 
significant differences. The results are expressed 
as mean ± standard deviation (SD). Differences 
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Among 25 patients enrolled for glabridin 
treatment 16 were male and 9 female with a 
average age of 49 ± 10 years (range: 24-58 
years) and a PD duration of 17 ± 25 months. The 
causes of end-stage renal disease diagnosed 
was glomerulonephritis, autosomal-dominant 
polycystic kidney disease, pyelonephritis and in 6 
patients cause could not be detected (Table 1). 
 
Table 1: The end-stage renal disease causes in the 
study patients 
 
Cause Patients (%) 
Glomerulonephritis 8 (32) 
ADPKDa 3 (12) 
Pyelonephritis 4 (16) 
Primary nephrosclerosis 4 (16) 
Unknown or others 6 (24) 
Total 25 
aADPKD = autosomal-dominant polycystic kidney 
disease 
 
Twenty one patients suffered from continuous 
ambulatory PD and 4 patients from continuous 
cycling PD. The examination of various 
parameters such as glucose, blood urea 
nitrogen, creatinine, sodium, potassium, calcium, 
phosphorus, albumin, cholesterol, hs-CRP, and 
hemoglobin before and after 6 months of 
glabridin treatment revealed no significant 
difference (Table 2). However, a significant 
decrease in the peritoneal membrane function 
decline (UF, D4/D0 glucose, Kt/V urea) was 
observed at the end of the treatment. 
 
The biochemical examination of the residual 
glomerular filtration rate (GFR) showed a 
significant decrease by the end of 6 months of 
glabridin treatment (3.52 ± 4.31 mL/min) 
compared with baseline (6.11 ± 4.65 mL/min). 
Glabridin treatment (25.89 ± 9.78 U/mL) also 
caused a significant increase in mean dialysate 
CA125 after 6 months compared with baseline 
(18.13± 9.32 U/mL). On the other hand, glabridin 
treatment induced no significant change in serum 
profibrotic markers such as VEGF, TGF-β, and 
CTGF (Table 3). 
 





Baseline After Glabridin treatment  




143 ± 18 
91 ± 12 
 
129 ± 19 




Body mass index (kg/m2) 27±6.1 27±4.5 0.281 
Glucose (mg/dL) 108±38 128±58 0.137 
BUN (mg/dL) 51±12 67±19 0.121 
Creatinine (mg/dL) 6.8±2.5 7.5±3.0 0.325 
Sodium (mmol/L) 141±5 134±5 0.119 
Potassium (mmol/L) 4.2±0.3 4.5±0.3 0.343 
Ca×P 38.5±9.4 45.0±9.5 0.153 
Albumin (g/dL) 3.80±0.32 3.63±0.42 0.397 





198 ± 42 
 
191 ± 34 
 
0.543 
129 ± 45 112 ± 42 0.432 
hs-CRP (mg/L) 12.1±5.2 7.6±4.45 0.213 
Hemoglobin (g/dL) 12.7±0.8 10.5±0.7 0.356 
Total Kt/Vurea 3.2±1.0 2.3±1.0 0.214 
Ultrafiltration (mL/day) 674 ± 123 742 ± 134 0.487 
D4/D0 glucose 0.51 ± 0.32 0.34 ± 0.35 0.196 
Residual GFR (mL/min) 6.4 ± 2.9 4.0 ± 4.02 0.014 
aMean ± standard error of the mean. BUN = blood urea nitrogen; Ca×P = calcium-phosphorus product; LDL = 
low-density lipoprotein; hs-CRP = high-sensitivity C-reactive protein; D4/D0 = 4-hour–to–initial dialysate 
concentration ratio; GFR = glomerular filtration rate 
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Table 3: Profibrotic markers and cancer antigen 125 (CA125) levels 
 
Parameter Value P-value 
 Baseline After Glabridin treatment  
In serum    
VEGF (pg/mL) 297 ± 52 372 ± 58 0.489 
TGF-β (pg/mL) 9898 ± 702 10604 ± 9928 0.6.54 
CTGF (pg/mL) 3387 ± 309 3811 ± 588 0.805 
In dialysate    
CA125 (U/mL) 19.7 ± 3.2 25.6 ± 2.7 0.031 
aMean ± standard error of the mean. VEGF = vascular endothelial growth factor; TGF-β = transforming growth 




There is development of alterations in the 
peritoneal membrane due to long term PD on 
regular contact with bio-incompatible 
components of dialysis solution [1]. A reduction 
in peritoneal thickness and enhancement of UF 
volume by ACEI whereas preservation of RRF 
and enhancement of peritoneal creatinine 
clearance by ARB after one year of PD initiation 
was reported [4,11]. The present study 
demonstrates the effect of glabridin on peritoneal 
function and RRF in patients on PD. Glabridin 
treatment for 6 months did not induce any 
significant difference in profibrotic markers or in 
parameters of peritoneal membrane function 
(UF, Kt/V, D4/D0 glucose). However the 
dialysate levels of CA125, a useful marker of 
mesothelial cell mass were significantly 
increased on glabridin treatment after 6 months. 
It has been shown that treatment of mesothelial 
cell culture to high concentrations of glucose 
caused increase in RAAS activation and 
angiotensinogen II led to an enhancement of 
TGF-β. TGF-β plays a vital role as the mediator 
in the development of fibrosis [3]. 
 
Our results revealed no significant difference in 
the levels of serum profibrotic markers (VEGF, 
TGF-β, CTGF) after 6 months of glabridin 
treatment. The levels of these profibrotic markers 
are expected to increase during the 6 month 
period after PD initiation in untreated patients. 
Among various alterations in the peritoneal 
membrane induced due to long term PD, loss of 
mesothelial cells is one such alteration. Loss of 
mesothelial cells is indicated by the dialysate 
CA125 with respect to the effect of the cell mass 
on mesothelium [15]. Local CA125 is released by 
peritoneal mesothelial cells within the peritoneum 
[16] and studies have shown a relation between 
the number of mesothelial cells in peritoneal 
effluent from PD patients and effluent CA125 
concentration. In patients with peritoneal 
sclerosis low CA125 values have been observed. 
Glabridin treatment caused a significant 
enhancement in effluent CA125 after 6 months of 
the treatment. Thus, glabridin treatment leads to 




The findings of this study indicate that glabridin 
treatment induces a decrease in the loss of 
peritoneal function, suppresses the expected 
elevation in profibrotic markers, and increases 
mesothelial cell mass in PD patients. Therefore, 
glabridin is a potent candidate for the treatment 
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